# France Vascular Embolization Market

> France Vascular Embolization Market Research Report: Size, Share, Trend Analysis By Embolization Technique (Coiling Devices, Non-coiling Devices) andBy Applications (Peripheral Vascular Disease, Oncology, Neurology, Urology, Other) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 9.66%
- **2024:** $ 130.51 Million
- **2025:** $ 143.12 Million
- **2035:** $ 360 Million
- **Key Players:** Medtronic (US), Boston Scientific (US), Terumo Corporation (JP), Johnson & Johnson (US), Stryker Corporation (US), B. Braun Melsungen AG (DE), Cook Medical (US), Abbott Laboratories (US), AngioDynamics (US)

**Report ID:** MRFR/MED/50297-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** February 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/france-vascular-embolization-market-52055

---

## Market Summary

## **France Vascular Embolization Market Overview**

As per MRFR analysis, the France Vascular Embolization Market Size was estimated at 85.58 (USD Million) in 2023. The France Vascular Embolization Market Industry is expected to grow from 94.05(USD Million) in 2024 to 420 (USD Million) by 2035. The France Vascular Embolization Market CAGR (growth rate) is expected to be around 14.573% during the forecast period (2025 - 2035).

### **Key France Vascular Embolization Market Trends Highlighted**

Several critical market drivers are currently propelling the expansion of the France [Vascular Embolization Market](../../../reports/vascular-embolization-market-11872). The demand for vascular embolization procedures has substantially increased due to the rise in the prevalence of vascular and neurovascular diseases, including aneurysms and arteriovenous malformations. The French healthcare system is fostering a favorable environment for the adoption of innovative embolization products by investing in sophisticated medical technologies to enhance patient care and outcomes. In addition, the French government's efforts to prioritize minimally invasive surgical procedures are consistent with global healthcare trends, thereby providing patients with improved recovery experiences. 

There are opportunities for businesses to capture segments of the market by concentrating on the development of biocompatible and highly effective embolization agents. Research and development in the field of embolic materials, including new bioresorbable options, offer opportunities for innovation that can meet the changing requirements of both healthcare providers and patients. Furthermore, the potential for market expansion and product adoption could be enhanced through partnerships with healthcare institutions throughout France. 

In recent years, there has been a significant increase in the integration of digital technologies into medical procedures, such as vascular embolization. Hospitals and clinics in France are implementing advanced imaging and navigation systems to improve the precision of procedures, thereby reducing complications and enhancing outcomes.Increasing acceptance by medical personnel and increasing awareness of the advantages of vascular embolization techniques among patients are contributing factors to this upward trend.

In general, the French market is distinguished by its emphasis on the enhancement of healthcare quality through technological advancements and innovative treatment methods, which will position it for sustainable growth in the years ahead.

Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review**

## **France Vascular Embolization Market Drivers**

### **Rising Incidence of Cancer Cases in France**

The increasing incidence of cancer cases in France is a significant driver for the France Vascular Embolization Market Industry. According to the French National Cancer Institute, approximately 382,000 new cancer cases were reported in France in 2020, with estimates projecting a continuous increase. This rising trend includes various forms of tumors, primarily in organs such as the liver and lungs, where vascular embolization is frequently utilized as a treatment.The French government has initiated several programs aimed at early detection and treatment of cancer, which further emphasizes the need for effective therapeutic interventions like embolization.

Notably, prominent organizations such as the French Society of Oncological Surgery are advocating for improved cancer management strategies, which will further increase the demand for vascular embolization procedures to treat tumors, driving the industry's growth.

### **Technological Advancements in Embolization Techniques**

Technological advancements in embolization techniques are playing a crucial role in the expansion of the France Vascular Embolization Market Industry. Recent innovations, such as the development of advanced embolic agents and devices, have significantly improved the efficacy and safety of these procedures. For instance, the introduction of biocompatible materials and drug-eluting beads has enhanced treatment outcomes.

According to the French Ministry of Health, hospitals across the country are investing in state-of-the-art medical equipment to support these advanced techniques, ensuring that patients have access to the latest treatment options.Established medical organizations like the French Society of Radiology are also encouraging the adoption of cutting-edge embolization technologies, which facilitate faster recovery times and fewer complications, thereby positively impacting market growth.

### **Increasing Awareness and Acceptance of Minimally Invasive Procedures**

The growing awareness and acceptance of minimally invasive procedures among healthcare professionals and patients are significantly influencing the France Vascular Embolization Market Industry. As patients become more informed about the benefits of less invasive interventions over traditional surgical methods, there is a notable shift in preferences towards procedures such as vascular embolization.

Surveys from healthcare bodies indicate that about 70% of patients in France prefer minimally invasive treatments due to their reduced recovery times and lower risk of complications.The French Health Authority is actively promoting the advantages of minimally invasive techniques, encouraging hospitals to expand their offerings to meet patient demand. This movement towards patient-centric care is driving an increase in vascular embolization procedures across the country.

### **Government Initiatives Supporting Healthcare Innovations**

Government initiatives aimed at supporting healthcare innovations significantly boost the France Vascular Embolization Market Industry. The French government has launched several programs focusing on enhancing healthcare infrastructure and promoting research and development (R&D) in medical technologies. For instance, the 'Investments for the Future' program allocates substantial funding to support innovative healthcare solutions, including advancements in embolization treatments.The French Ministry of Health reports that these initiatives have led to an increase in partnerships between medical institutions and technology companies, fostering a collaborative environment that stimulates growth in the market.

As more hospitals gain access to cutting-edge embolization technologies due to government backing, the demand for these procedures is expected to rise, positively impacting the overall market trajectory.

## **France Vascular Embolization Market Segment Insights**

### **Vascular Embolization Market Embolization Technique Insights**

The France Vascular Embolization Market is witnessing significant growth, particularly within the Embolization Technique segment, which plays a crucial role in managing various vascular conditions. This segment encompasses innovative approaches designed to block abnormal blood vessels, thereby treating conditions such as tumors, aneurysms, and arteriovenous malformations. The techniques, which include both Coiling Devices and Non-coiling Devices, contribute to improved patient outcomes, and the French healthcare system has incorporated these advanced methods into standard practice.Coiling Devices, known for their effectiveness in treating cerebral aneurysms, have seen widespread adoption within the country, driven by the increasing prevalence of neurological disorders.

Meanwhile, Non-coiling Devices are becoming more prominent, particularly for their versatility in several embolization procedures beyond neurological applications. 

This is pertinent as the shift towards minimally invasive procedures aligns with broader healthcare trends favoring quicker recovery times and reduced hospital stays. Additional factors propelling the growth in the Embolization Technique segment include an aging population, advances in medical technology, and increased investment in healthcare infrastructure in France.Moreover, rising awareness about interventional radiology among patients and healthcare providers further enhances the segment's attractiveness. However, challenges such as the high costs associated with some embolization techniques and potential risks of complications must be addressed to sustain market growth.

Overall, the dynamics of the France Vascular Embolization Market reveal a landscape rich with opportunities, driven by innovative techniques and a commitment to improving clinical efficiencies through advanced embolization methods.

Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review**

### **Vascular Embolization Market Application Insights**

The France Vascular Embolization Market encompasses pivotal applications in various medical fields, notably including Peripheral Vascular Disease, Oncology, Neurology, and Urology. Each of these applications plays a critical role in addressing diverse health issues, with Peripheral Vascular Disease seeing increased focus due to rising incidence rates in the aging population.

Furthermore, the Oncology segment is significant as it addresses the demand for effective cancer treatment solutions through embolization techniques, which provide minimally invasive options for tumor control.Neurology is another crucial area where vascular embolization techniques are applied, especially in treating conditions like arteriovenous malformations and aneurysms, highlighting the importance of this segment in stroke prevention and management. 

The Urology application has been gaining traction as well, with embolization being utilized in the management of renal tumors, thus contributing valuable treatment alternatives. The Other application category further reinforces the versatility of vascular embolization, signaling its expanding relevance across various specialties in the medical field.Overall, these segments contribute to the growing significance of the France Vascular Embolization Market, driven by advancements in medical technology and increasing awareness of catheter-based procedures.

## **France Vascular Embolization Market Key Players and Competitive Insights**

The France Vascular Embolization Market showcases a diverse and dynamic competitive landscape, characterized by a blend of established players and emerging entities striving for market share through innovative product offerings and strategic initiatives. The sector is primarily driven by advancements in medical technology, an increasing patient base, and a growing presence of minimally invasive procedures. As a significant part of the healthcare system, vascular embolization is witnessing robust growth due to a rising prevalence of vascular diseases and the accompanying demand for effective therapeutic interventions. 

In this context, various companies are striving to enhance their market position by leveraging research and development capabilities to introduce cutting-edge solutions tailored to the needs of healthcare providers and patients.AngioDynamics has established a prominent position in the France Vascular Embolization Market through its array of specialized products designed for the embolization of various vascular conditions. 

The company's strengths lie in its extensive portfolio of innovative medical devices and its commitment to enhancing patient outcomes by focusing on minimally invasive treatments. AngioDynamics has cultivated strong relationships with healthcare professionals, ensuring a steady market presence enhanced by robust distribution networks. The company's emphasis on quality, coupled with strategic partnerships, allows it to maintain a significant competitive edge in the vascular embolization sector in France, positioning it as a trusted provider within the healthcare ecosystem.Neurotherapeutics has made noteworthy contributions to the France Vascular Embolization Market, focusing on advanced therapies targeting neurological conditions that require embolization techniques. 

The company offers key services and products, including specialized embolization agents and delivery systems, which are crucial for treating complex vascular formations. Neurotherapeutics strengthens its market presence through continuous innovation and an emphasis on clinical efficacy, positioning its products favorably among healthcare providers. The company has pursued strategic mergers and acquisitions to enhance its technology portfolio and subsequently consolidate its market position in France, enabling it to expand its product offerings and drive growth in the vascular embolization sector. Its focus on developing niche solutions further strengthens its ability to meet the evolving needs of medical practitioners and patients alike.

### **Key Companies in the France Vascular Embolization Market Include:**

## **France Vascular Embolization Market Industry Developments**

Recent developments in the France Vascular Embolization Market show a growing interest in innovative treatment options and technological advancements. Companies such as AngioDynamics, Neurotherapeutics, Johnson and Johnson, and B. Braun Melsungen have been actively involved in expanding their product portfolios to cater to a rising demand for minimally invasive procedures. In August 2023, Johnson and Johnson announced the launch of a new vascular embolization device aimed at improving patient outcomes. Additionally, in September 2023, Terumo Corporation reported a partnership with local healthcare providers to enhance the availability of their embolization solutions across France. 

In terms of mergers and acquisitions, in July 2023, Abbott Laboratories successfully acquired a French medical device company that specializes in embolization technologies, marking a significant move to strengthen its market position in Europe. The valuation growth of firms in the France Vascular Embolization Market has been driven by increasing investment in Research and Development, which rising healthcare expenditures and a higher prevalence of vascular diseases have propelled. Over the last few years, this market has seen a robust growth trajectory supported by advancements in medical technologies and a focus on patient-centric treatment options.

## **France Vascular Embolization Market Segmentation Insights**

### **Vascular Embolization Market Embolization Technique****Outlook**

### **Vascular Embolization Market Application****Outlook**

## Market Drivers

### Supportive Reimbursement Policies

Supportive reimbursement policies in France are a significant driver for the vascular embolization market. The French healthcare system provides coverage for various embolization procedures, which encourages both patients and healthcare providers to opt for these treatments. The availability of reimbursement for innovative medical technologies enhances accessibility and affordability, making vascular embolization a viable option for many patients. Recent policy updates have expanded coverage for minimally invasive procedures, aligning with the growing trend towards such treatments. As reimbursement frameworks continue to evolve, they are likely to further stimulate the vascular embolization market by ensuring that patients can receive necessary interventions without financial burden.

### Increasing Prevalence of Vascular Diseases

The rising incidence of vascular diseases in France is a crucial driver for the vascular embolization market. Conditions such as aneurysms, arteriovenous malformations, and peripheral artery disease are becoming more common, necessitating effective treatment options. According to recent health statistics, approximately 30% of the French population is affected by some form of vascular disease, leading to a growing demand for innovative therapeutic solutions. This trend is likely to propel the vascular embolization market forward, as healthcare providers seek advanced techniques to manage these conditions. The increasing burden of vascular diseases emphasizes the need for timely interventions, thereby enhancing the market's growth potential. As the healthcare system in France continues to evolve, the focus on addressing vascular health issues will likely remain a priority, further driving the vascular embolization market's expansion.

### Advancements in Medical Imaging Technologies

The evolution of medical imaging technologies plays a pivotal role in the vascular embolization market. Enhanced imaging modalities, such as MRI, CT scans, and ultrasound, facilitate accurate diagnosis and treatment planning for vascular conditions. These advancements enable clinicians to visualize vascular structures in real-time, improving the precision of embolization procedures. In France, the integration of cutting-edge imaging technologies has been linked to a 25% increase in successful embolization outcomes. This trend not only boosts patient safety but also enhances the overall efficacy of treatments. As imaging technologies continue to advance, they are expected to further support the growth of the vascular embolization market by providing healthcare professionals with the tools necessary for optimal patient care.

### Growing Investment in Healthcare Infrastructure

The French government's commitment to enhancing healthcare infrastructure significantly impacts the vascular embolization market. Increased funding for hospitals and medical facilities has led to the acquisition of advanced medical equipment and technologies. This investment is crucial for improving the quality of care and expanding access to vascular embolization procedures. Reports indicate that healthcare spending in France is projected to rise by 5% annually, with a substantial portion allocated to interventional radiology and minimally invasive techniques. As healthcare facilities upgrade their capabilities, the vascular embolization market is likely to benefit from improved service delivery and patient outcomes. This trend underscores the importance of a robust healthcare infrastructure in fostering the growth of the vascular embolization market.

### Rising Awareness of Minimally Invasive Treatments

There is a notable increase in awareness regarding the benefits of minimally invasive treatments among both healthcare professionals and patients in France. This growing recognition is driving the demand for vascular embolization procedures, which are often associated with shorter recovery times and reduced hospital stays. Surveys indicate that approximately 70% of patients prefer minimally invasive options when available, reflecting a shift in patient expectations. As awareness campaigns and educational initiatives continue to proliferate, the vascular embolization market is expected to experience heightened interest and adoption. This trend suggests that as patients become more informed about their treatment options, the preference for vascular embolization will likely grow, further propelling market expansion.

## Future Outlook

The [Vascular Embolization Market](https://www.marketresearchfuture.com/reports/vascular-embolization-market-11872) in France is projected to grow at a 9.66% CAGR from 2025 to 2035, driven by technological advancements and increasing demand for minimally invasive procedures.

**New opportunities:**

- Development of biodegradable embolic agents for enhanced patient safety.
- Expansion of telemedicine platforms for remote embolization consultations.
- Investment in AI-driven imaging technologies to improve procedural accuracy.

By 2035, the vascular embolization market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Technique: Coiling Devices (Largest) vs. Non-coiling Devices (Fastest-Growing)

In the France vascular embolization market, coiling devices command a significant share, established as the largest segment due to their widespread acceptance in treating various vascular conditions. These devices, known for their reliability and efficacy, are preferred by practitioners for their proven outcomes and ease of use. In contrast, non-coiling devices, while currently smaller in market share, are rapidly gaining traction as they offer innovative solutions and treatment options that enhance procedural efficacy.

The growth of the non-coiling devices segment can be attributed to advancements in technology and increasing investments in healthcare innovation. As practitioners seek out alternatives that provide better outcomes and lower complication rates, non-coiling devices are emerging as a favorable choice. Factors such as an aging population and an increased prevalence of vascular diseases are driving the adoption of these alternatives, contributing to their status as the fastest-growing segment within the France vascular embolization market.

Technique: Coiling Devices (Dominant) vs. Non-coiling Devices (Emerging)

Coiling devices represent the dominant technique in the France vascular embolization market, known for their effectiveness in occluding blood vessels. These devices are typically made of soft, flexible wire carefully shaped to fit the geometry of the target vessel, providing secure placement and reducing the risk of recanalization. On the other hand, non-coiling devices include various innovative products like plugs and spheres that are rapidly emerging in the market. They use advanced materials and designs that facilitate easier deployment and might offer additional advantages in complex cases. As technology advances, the position and acceptance of non-coiling devices are expected to grow steadily, making them a notable competitor in this evolving landscape.

### By Application: Peripheral Vascular Disease (Largest) vs. Oncology (Fastest-Growing)

The France vascular embolization market is primarily divided among several application segments. Peripheral Vascular Disease commands the largest market share, reflecting the high prevalence of vascular conditions that necessitate embolization procedures. Oncology follows as a significant segment due to the rising incidences of tumors, leading to increased adoption of targeted embolization therapies. Other applications like Neurology and Urology also contribute but hold smaller shares in comparison.

Growth trends for the application segment reveal a robust shift towards minimally invasive procedures, with Oncology currently emerging as the fastest-growing area. Advances in technology and improved outcomes are driving this trend, as more healthcare providers opt for innovative embolization techniques. Increased awareness and screening for vascular diseases further bolster the growth in Peripheral Vascular Disease, indicating a dynamic landscape for the France vascular embolization market.

Peripheral Vascular Disease (Dominant) vs. Oncology (Emerging)

Peripheral Vascular Disease is characterized by a major need for advanced treatment solutions due to its high prevalence among aging populations. This segment dominates the market as healthcare providers increasingly adopt embolization techniques to address complex vascular issues. Conversely, the Oncology segment is marked by rapid advancements in technology and treatment methodologies, positioning it as an emerging area of focus. The rise in cancer cases continues to fuel demand for innovative therapies, pushing the boundaries of traditional treatment approaches. Both segments reflect the dual demand for effective solutions in chronic conditions, engaging various market players who contribute to ongoing research and development in the France vascular embolization market.

## Competitive Benchmarking

The vascular embolization market in France is characterized by a dynamic competitive landscape, driven by technological advancements and an increasing prevalence of vascular diseases. Key players such as Medtronic (US), Boston Scientific (US), and Terumo Corporation (JP) are at the forefront, focusing on innovation and strategic partnerships to enhance their market presence. Medtronic (US) emphasizes the development of minimally invasive solutions, while Boston Scientific (US) is known for its robust product pipeline and commitment to research and development. Terumo Corporation (JP) leverages its expertise in medical devices to expand its offerings in embolization products, thereby shaping a competitive environment that prioritizes technological innovation and patient outcomes.
In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and improve supply chain efficiency. The market structure appears moderately fragmented, with several players vying for market share. This fragmentation allows for a diverse range of products and services, fostering competition that drives innovation. The collective influence of these key players is significant, as they continuously adapt to market demands and regulatory changes, ensuring their offerings remain relevant and effective.
In October 2025, Medtronic (US) announced the launch of a new embolization device designed to enhance precision in vascular procedures. This strategic move is likely to strengthen its position in the market by addressing the growing demand for advanced embolization solutions. The introduction of this device not only showcases Medtronic's commitment to innovation but also reflects its responsiveness to evolving clinical needs, potentially leading to increased market share.
In September 2025, Boston Scientific (US) entered into a partnership with a leading French healthcare provider to enhance the distribution of its embolization products. This collaboration is expected to expand Boston Scientific's reach within the French market, allowing for better access to its innovative solutions. Such strategic alliances are crucial in navigating the complexities of the healthcare landscape, as they enable companies to leverage local expertise and improve service delivery.
In August 2025, Terumo Corporation (JP) acquired a small French medical device company specializing in embolization technologies. This acquisition is indicative of Terumo's strategy to bolster its product portfolio and enhance its competitive edge in the market. By integrating new technologies and expertise, Terumo aims to accelerate its growth trajectory and respond more effectively to customer needs.
As of November 2025, current trends in the vascular embolization market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence (AI) in product development. Strategic alliances are increasingly shaping the competitive landscape, allowing companies to pool resources and expertise. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift suggests that companies that prioritize these areas will likely emerge as leaders in the vascular embolization market.

## Recent News & Developments

Recent developments in the France Vascular Embolization Market show a growing interest in innovative treatment options and technological advancements. Companies such as AngioDynamics, Neurotherapeutics, Johnson and Johnson, and B. Braun Melsungen have been actively involved in expanding their product portfolios to cater to a rising demand for minimally invasive procedures. In August 2023, Johnson and Johnson announced the launch of a new vascular embolization device aimed at improving patient outcomes. Additionally, in September 2023, Terumo Corporation reported a partnership with local healthcare providers to enhance the availability of their embolization solutions across France. 

In terms of mergers and acquisitions, in July 2023, Abbott Laboratories successfully acquired a French medical device company that specializes in embolization technologies, marking a significant move to strengthen its market position in Europe. The valuation growth of firms in the France Vascular Embolization Market has been driven by increasing investment in Research and Development, which rising healthcare expenditures and a higher prevalence of vascular diseases have propelled. Over the last few years, this market has seen a robust growth trajectory supported by advancements in medical technologies and a focus on patient-centric treatment options.

## Report Scope

| MARKET SIZE 2024 | 130.51(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 143.12(USD Million) |
| MARKET SIZE 2035 | 360.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 9.66% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Medtronic (US), Boston Scientific (US), Terumo Corporation (JP), Johnson & Johnson (US), Stryker Corporation (US), B. Braun Melsungen AG (DE), Cook Medical (US), Abbott Laboratories (US), AngioDynamics (US) |
| Segments Covered | Technique, Application |
| Key Market Opportunities | Advancements in minimally invasive techniques enhance growth potential in the vascular embolization market. |
| Key Market Dynamics | Technological advancements and regulatory changes drive growth in the vascular embolization market in France. |
| Countries Covered | France |

## Frequently Asked Questions

**Q: What was the market valuation of the vascular embolization market in 2024?**
A: The market valuation was $130.51 Million in 2024.

**Q: What is the projected market valuation for the vascular embolization market by 2035?**
A: The projected market valuation for 2035 is $360.0 Million.

**Q: What is the expected CAGR for the vascular embolization market during the forecast period 2025 - 2035?**
A: The expected CAGR for the market during this period is 9.66%.

**Q: Which companies are considered key players in the vascular embolization market?**
A: Key players include Medtronic, Boston Scientific, Terumo Corporation, Johnson & Johnson, Stryker Corporation, B. Braun Melsungen AG, Cook Medical, Abbott Laboratories, and AngioDynamics.

**Q: What are the main techniques used in the vascular embolization market?**
A: The main techniques include coiling devices and non-coiling devices, with non-coiling devices valued at $80.51 Million to $220.0 Million.

**Q: How does the application of oncology compare to other applications in the vascular embolization market?**
A: Oncology applications are valued between $40.0 Million and $120.0 Million, indicating a strong market presence compared to others.

**Q: What was the valuation range for coiling devices in the vascular embolization market?**
A: The valuation range for coiling devices was between $50.0 Million and $140.0 Million.

**Q: What is the valuation range for peripheral vascular disease applications in the vascular embolization market?**
A: The valuation range for peripheral vascular disease applications is between $30.0 Million and $80.0 Million.

**Q: What is the significance of the vascular embolization market in France?**
A: The vascular embolization market in France is poised for growth, with a projected increase in valuation from $130.51 Million in 2024 to $360.0 Million by 2035.

**Q: How do the valuations of urology applications compare to other segments in the vascular embolization market?**
A: Urology applications are valued between $20.0 Million and $50.0 Million, which is lower than oncology and peripheral vascular disease applications.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/france-vascular-embolization-market-52055*